XML 60 R45.htm IDEA: XBRL DOCUMENT
v3.20.2

Summary of Significant Accounting Policies - Medical Aesthetics Impairment and Other Activity (Details) - USD ($) | 3 Months Ended | 12 Months Ended |
--- | --- | --- | ---
Sep. 26, 2020 | Mar. 28, 2020 | Dec. 28, 2019 | Mar. 30, 2019 | Mar. 31, 2018 | Sep. 28, 2019 | Oct. 01, 2018
Business Acquisition [Line Items] |  |  |  |  |  |  |
Impairment charge |  |  | $ 30,200,000 | $ 685,400,000 |  |  |
Goodwill and Intangible Asset Impairment |  |  |  |  |  | $ 685,400,000 |
Acessa Health [Member] | Developed technology |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |
Identifiable intangible assets: | $ 127,000,000.0 |  |  |  |  |  |
Acessa Health [Member] | Trade names |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |
Identifiable intangible assets: | 1,200,000 |  |  |  |  |  |
Focal Therapeutics | Developed technology |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |
Identifiable intangible assets: |  |  |  |  |  |  | $ 83,100,000
Focal Therapeutics | Trade names |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |
Identifiable intangible assets: |  |  |  |  |  |  | 2,700,000
Focal Therapeutics | In-process research and development |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |
Identifiable intangible assets: |  |  |  |  |  |  | $ 11,400,000
In process research and development reclassified to developed technology |  |  |  |  |  | $ 5,500,000 |
Medical Aesthetics |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |
Impairment charge |  | $ 30,200,000 |  |  |  |  |
Distribution agreement [Member] | Medical Aesthetics |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |
Impairment charge | 27,700,000 | 1,200,000 |  |  |  |  |
Customer relationships | Medical Aesthetics |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |
Impairment charge | 22,400,000 | 900,000 |  |  |  |  |
Trade names | Medical Aesthetics |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |
Impairment charge | 48,600,000 | 2,000,000.0 |  |  |  |  |
Developed Technology [Member] | Medical Aesthetics |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |
Impairment charge | 576,900,000 | $ 24,100,000 |  |  |  |  |
Property, Plant and Equipment [Member] | Medical Aesthetics |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |
Impairment charge | $ 9,800,000 |  |  |  |  |  |
In-process research and development | Medical Aesthetics |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |
Impairment charge |  |  |  |  | $ 46,000,000.0 |  |

X
- Definition In process research and development reclassified to developed technology + References No definition available. + Details
Name: | holx_Inprocessresearchanddevelopmentreclassifiedtodevelopedtechnology
Namespace Prefix: | holx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 45 -Paragraph 4 -URI http://asc.fasb.org/extlink&oid=109226348&loc=d3e2420-110228 + Details
Name: | us-gaap_AssetImpairmentCharges
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_BusinessAcquisitionLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of intangible assets, excluding goodwill, acquired at the acquisition date. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 20 -Section 50 -Paragraph 1 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=116869197&loc=d3e4845-128472 + Details
Name: | us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Total loss recognized during the period from the impairment of goodwill plus the loss recognized in the period resulting from the impairment of the carrying amount of intangible assets, other than goodwill. + References No definition available. + Details
Name: | us-gaap_GoodwillAndIntangibleAssetImpairment
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=holx_AcessaHealthMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=holx_FocalTherapeuticsInc.Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=holx_MedicalAestheticsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FairValueByAssetClassAxis=holx_DistributionagreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FairValueByAssetClassAxis=us-gaap_CustomerRelationshipsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FairValueByAssetClassAxis=us-gaap_TradeNamesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FairValueByAssetClassAxis=holx_DevelopedTechnologyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FairValueByAssetClassAxis=us-gaap_PropertyPlantAndEquipmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FairValueByAssetClassAxis=us-gaap_InProcessResearchAndDevelopmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |